The Von Hippel-Lindau (VHL) protein is a crucial tumor suppressor protein encoded by the VHL gene. This protein plays a significant role in the regulation of cellular responses to oxygen levels. Mutations in the VHL gene are associated with Von Hippel-Lindau disease, a rare genetic disorder characterized by the development of tumors and cysts in various parts of the body .
The primary function of the VHL protein is to act as the substrate recognition component of an E3 ubiquitin ligase complex. This complex is responsible for the ubiquitination and subsequent degradation of hypoxia-inducible factors (HIFs), which are transcription factors that regulate gene expression in response to oxygen levels . Under normal oxygen conditions, the VHL protein binds to HIF1α, leading to its degradation. However, under hypoxic conditions, this binding does not occur, allowing HIF1α to activate the transcription of genes involved in angiogenesis and other processes .
Von Hippel-Lindau disease is caused by mutations in the VHL gene, leading to the production of dysfunctional VHL protein. This results in the accumulation of HIFs and the uncontrolled growth of cells, forming tumors and cysts in various organs, including the brain, spinal cord, retina, kidneys, pancreas, and adrenal glands . The disease can be inherited or occur spontaneously, and its clinical manifestations depend on the location and size of the tumors .
The Mouse Anti Human VHL Protein antibody is a monoclonal antibody used in research to study the VHL protein. This antibody is specifically designed to bind to the human VHL protein, allowing researchers to detect and quantify its presence in various biological samples. The use of this antibody is crucial in understanding the role of VHL protein in cellular processes and its implications in diseases like Von Hippel-Lindau disease .
The Mouse Anti Human VHL Protein antibody is widely used in various research applications, including: